Literature DB >> 29925470

Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.

Diogo Torres1, Chen Wang2, Amanika Kumar1, Jamie N Bakkum-Gamez1, Amy L Weaver3, Michaela E McGree4, Gottfried E Konecny4, Ellen L Goode3, William A Cliby5.   

Abstract

OBJECTIVE: To investigate the relationship between molecular subtype, intraperitoneal (IP) disease dissemination patterns, resectability, and overall survival (OS) in advanced high-grade serous ovarian cancer (HGSOC).
METHODS: Patients undergoing primary surgery for stage III-IV HGSOC at Mayo Clinic from 1994 to 2011 were categorized into three IP disease dissemination patterns: upper abdominal or miliary; lower abdominal; and pelvic. Residual disease was defined as 0 (RD0), 0.1-0.5, 0.6-1.0, or >1 cm. Molecular subtypes were derived from Agilent 4x44k tumor mRNA expression profiles and categorized as mesenchymal (MES) or non-mesenchymal (non-MES).
RESULTS: Operative and molecular data was available for 334 patients. Median OS was shorter in patients with MES compared to non-MES subtypes (34.2 vs 44.6 months; P = 0.009). Patients with MES subtype were more likely to have upper abdominal/miliary disease compared to non-MES subtype (90% vs. 72%, P < 0.001). For patients with upper abdominal/miliary disease, complete resection (RD0) was less common in MES compared to non-MES subtypes (11% vs. 27%, P = 0.004). On multivariable analysis, RD was the only factor associated with OS (P < 0.001). In patients with upper abdominal/miliary disease, though less commonly achieved, RD0 improved survival irrespective of molecular subtype (median OS of 69.2 and 57.9 months for MES and non-MES subtype).
CONCLUSIONS: Our results support a paradigm in which molecular subtype is an important driver of dissemination pattern; this in turn impacts resectability and ultimately survival. Consequently mesenchymal subtype is associated with much lower rates of complete resection, though RD0 remains the most important independent predictor of survival.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epithelial ovarian cancer; High-grade serous ovarian cancer; Mesenchymal; Molecular subtype; Residual disease; TCGA subtype

Mesh:

Year:  2018        PMID: 29925470      PMCID: PMC8251658          DOI: 10.1016/j.ygyno.2018.06.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

1.  Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.

Authors:  Neil S Horowitz; Austin Miller; Bunja Rungruang; Scott D Richard; Noah Rodriguez; Michael A Bookman; Chad A Hamilton; Thomas C Krivak; G Larry Maxwell
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer.

Authors:  Jalid Sehouli; Filiz Senyuva; Christina Fotopoulou; Ulf Neumann; Carsten Denkert; Lichtenegger Werner; Oskay-Ozcelik Gülten
Journal:  J Surg Oncol       Date:  2009-06-01       Impact factor: 3.454

3.  Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.

Authors:  Sumer Wallace; Amanika Kumar; Michaela Mc Gree; Amy Weaver; Andrea Mariani; Carrie Langstraat; Sean Dowdy; Jamie Bakkum-Gamez; William Cliby
Journal:  Gynecol Oncol       Date:  2017-01-31       Impact factor: 5.482

4.  Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.

Authors:  Kevin H Eng; Kayla Morrell; Kristen Starbuck; Chandra Spring-Robinson; Aalia Khan; Dana Cleason; Levent Akman; Emese Zsiros; Kunle Odunsi; J Brian Szender
Journal:  Gynecol Oncol       Date:  2017-05-08       Impact factor: 5.482

Review 5.  A framework for a personalized surgical approach to ovarian cancer.

Authors:  Alpa M Nick; Robert L Coleman; Pedro T Ramirez; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2015-02-24       Impact factor: 66.675

6.  A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Authors:  Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Revathy B Iyer; Qin Zhou; Alexia Iasonos; John Denesopolis; Oliver Zivanovic; Kara C Long Roche; Yukio Sonoda; Robert L Coleman; Nadeem R Abu-Rustum; Hedvig Hricak; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2017-02-14       Impact factor: 5.482

7.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

8.  Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Karl C Podratz; William A Cliby
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

9.  Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.

Authors:  Diogo Torres; Amanika Kumar; Sumer K Wallace; Jamie N Bakkum-Gamez; Gottfried E Konecny; Amy L Weaver; Michaela E McGree; Ellen L Goode; William A Cliby; Chen Wang
Journal:  Gynecol Oncol       Date:  2017-09-28       Impact factor: 5.482

10.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

View more
  16 in total

1.  Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.

Authors:  Qing Zhang; Chen Wang; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-11-15       Impact factor: 5.482

2.  Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram.

Authors:  Haiming Li; Rui Zhang; Ruimin Li; Wei Xia; Xiaojun Chen; Jiayi Zhang; Songqi Cai; Yong'ai Li; Shuhui Zhao; Jinwei Qiang; Weijun Peng; Yajia Gu; Xin Gao
Journal:  Eur Radiol       Date:  2021-04-16       Impact factor: 5.315

3.  Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.

Authors:  Juan Chen; Xiaoyan Shi; Lan Xiao; Zelian Li; Zhimin Li; Lei Sun
Journal:  Cancer Med       Date:  2022-04-17       Impact factor: 4.711

4.  Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.

Authors:  Sotirios Lakis; Vassiliki Kotoula; Georgia-Angeliki Koliou; Ioannis Efstratiou; Sofia Chrisafi; Alexios Papanikolaou; Pantelis Zebekakis; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

5.  Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.

Authors:  Olga T Filippova; Pier Selenica; Fresia Pareja; Mahsa Vahdatinia; Yingjie Zhu; Xin Pei; Nadeem Riaz; Kara Long Roche; Dennis S Chi; Nadeem R Abu-Rustum; Lora H Ellenson; Jorge S Reis-Filho; Dmitriy Zamarin; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2021-03-03       Impact factor: 5.482

6.  Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer.

Authors:  Xibo Zhao; Shanshan Cong; Qiuyan Guo; Yan Cheng; Tian Liang; Jing Wang; Guangmei Zhang
Journal:  Front Cell Dev Biol       Date:  2021-04-23

7.  Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).

Authors:  Aline Talhouk; Joshy George; Chen Wang; Ellen L Goode; Susan J Ramus; Jennifer A Doherty; David D Bowtell; Michael S Anglesio; Timothy Budden; Tuan Zea Tan; Derek S Chiu; Stefan Kommoss; Huei San Leong; Stephanie Chen; Maria P Intermaggio; Blake Gilks; Tayyebeh M Nazeran; Mila Volchek; Wafaa Elatre; Rex C Bentley; Janine Senz; Amy Lum; Veronica Chow; Hanwei Sudderuddin; Robertson Mackenzie; Samuel C Y Leong; Geyi Liu; Dustin Johnson; Billy Chen; Aocs Group; Jennifer Alsop; Susana N Banerjee; Sabine Behrens; Clara Bodelon; Alison H Brand; Louise Brinton; Michael E Carney; Yoke-Eng Chiew; Kara L Cushing-Haugen; Cezary Cybulski; Darren Ennis; Sian Fereday; Renée T Fortner; Jesús García-Donas; Aleksandra Gentry-Maharaj; Rosalind Glasspool; Teodora Goranova; Casey S Greene; Paul Haluska; Holly R Harris; Joy Hendley; Brenda Y Hernandez; Esther Herpel; Mercedes Jimenez-Linan; Chloe Karpinskyj; Scott H Kaufmann; Gary L Keeney; Catherine J Kennedy; Martin Köbel; Jennifer M Koziak; Melissa C Larson; Jenny Lester; Liz-Anne Lewsley; Jolanta Lissowska; Jan Lubiński; Hugh Luk; Geoff Macintyre; Sven Mahner; Iain A McNeish; Janusz Menkiszak; Nikilyn Nevins; Ana Osorio; Oleg Oszurek; José Palacios; Samantha Hinsley; Celeste L Pearce; Malcolm C Pike; Anna M Piskorz; Isabelle Ray-Coquard; Valerie Rhenius; Cristina Rodriguez-Antona; Raghwa Sharma; Mark E Sherman; Dilrini De Silva; Naveena Singh; Peter Sinn; Dennis Slamon; Honglin Song; Helen Steed; Euan A Stronach; Pamela J Thompson; Aleksandra Tołoczko; Britton Trabert; Nadia Traficante; Chiu-Chen Tseng; Martin Widschwendter; Lynne R Wilkens; Stacey J Winham; Boris Winterhoff; Alicia Beeghly-Fadiel; Javier Benitez; Andrew Berchuck; James D Brenton; Robert Brown; Jenny Chang-Claude; Georgia Chenevix-Trench; Anna deFazio; Peter A Fasching; María J García; Simon A Gayther; Marc T Goodman; Jacek Gronwald; Michelle J Henderson; Beth Y Karlan; Linda E Kelemen; Usha Menon; Sandra Orsulic; Paul D P Pharoah; Nicolas Wentzensen; Anna H Wu; Joellen M Schildkraut; Mary Anne Rossing; Gottfried E Konecny; David G Huntsman; Ruby Yun-Ju Huang
Journal:  Clin Cancer Res       Date:  2020-06-17       Impact factor: 13.801

8.  Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.

Authors:  Allison L Hunt; Nicholas W Bateman; Waleed Barakat; Sasha Makohon-Moore; Brian L Hood; Kelly A Conrads; Ming Zhou; Valerie Calvert; Mariaelena Pierobon; Jeremy Loffredo; Tracy J Litzi; Julie Oliver; Dave Mitchell; Glenn Gist; Christine Rojas; Brian Blanton; Emma L Robinson; Kunle Odunsi; Anil K Sood; Yovanni Casablanca; Kathleen M Darcy; Craig D Shriver; Emanuel F Petricoin; Uma N M Rao; G Larry Maxwell; Thomas P Conrads
Journal:  iScience       Date:  2021-06-21

9.  Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?

Authors:  Ye Hu; Barbie Taylor-Harding; Yael Raz; Marcela Haro; Maria Sol Recouvreux; Enes Taylan; Jenny Lester; Joshua Millstein; Ann E Walts; Beth Y Karlan; Sandra Orsulic
Journal:  Front Cell Dev Biol       Date:  2020-07-17

10.  Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

Authors:  S Y Cindy Yang; Stephanie Lheureux; Katherine Karakasis; Julia V Burnier; Jeffery P Bruce; Derek L Clouthier; Arnavaz Danesh; Rene Quevedo; Mark Dowar; Youstina Hanna; Tiantian Li; Lin Lu; Wei Xu; Blaise A Clarke; Pamela S Ohashi; Patricia A Shaw; Trevor J Pugh; Amit M Oza
Journal:  Genome Med       Date:  2018-10-31       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.